Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
29 juil. 2024 05h00 HE | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
31 mai 2024 08h00 HE | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
29 mai 2024 08h00 HE | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Captura de pantalla 2023-11-10 082355 big.png
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
21 mai 2024 08h00 HE | Lipella Pharmaceuticals Inc.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
17 avr. 2024 08h00 HE | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
05 avr. 2024 08h00 HE | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
03 avr. 2024 08h00 HE | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
05 mars 2024 08h00 HE | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
20 févr. 2024 08h00 HE | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
20 déc. 2023 08h00 HE | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished